摘要
大麻(Cannabis sativa)是一种古老的药用植物,常被用于缓解疼痛和癫痫性发作。然而,大麻素具有成瘾性,这限制了它们的临床使用。大麻二酚(cannabidiol,CBD)作为一种没有精神活性的大麻成分,不良反应明显小于Δ9-四氢大麻酚(Δ9-tetrahydrocannabinol,THC),因此受到了广泛关注。研究发现,CBD对多种神经精神疾病均有改善作用,但具体的作用机制尚未明确。由于它与经典的大麻素受体间的亲和力低,越来越多的研究开始关注内源性大麻素系统以外的其他靶点。本综述主要总结CBD在癫痫、神经病理性疼痛、焦虑症和抑郁症中的作用和分子机制。
Cannabis sativa,one of the ancient medicinal plants,has been used to alleviate pain and seizures.However,cannabinoids are often addictive,which limits their clinical use.Cannabidiol(CBD)as a non-psychoactive component of Cannabis sativa,has much weaker adverse effects thanΔ9-tetrahydrocannabinol(THC)and therefore has received widespread attention.CBD has been found to ameliorate a variety of neuropsychiatric diseases,but the precise mechanism(s)of action are still unclear.Due to its low affinity for classical cannabinoid receptors current studies are focusing on other targets outside the endocannabinoid system.In the present review we mainly summarize the effects and molecular mechanisms of CBD in neuropsychiatric disorders,including epilepsy,neuropathic pain,anxiety,and depression.
作者
吴军
于海波
WU Jun;YU Hai-bo(State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100050,China)
出处
《药学学报》
CAS
CSCD
北大核心
2020年第12期2800-2810,共11页
Acta Pharmaceutica Sinica
基金
重大新药创制科技重大专项(2018ZX09711001-004-001)
新药作用机制研究与药效评价北京市重点实验室(BZ0150).
